SCHEMBL5740650

SCHEMBL5740650

COc1c(I)cc(CC(=O)NO)cc1I

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC6 Q9UBN7 2/20 0.47
HDAC8 Q9BY41 2/20 0.47
MEN1 O00255 1/20 0.47
KMT2A Q03164 1/20 0.47
THRA P10827 3/20 0.46
THRB P10828 3/20 0.46
PPARG P37231 3/20 0.46
RXRA P19793 2/20 0.46
ITGB3 P05106 1/20 0.46
ITGAV P06756 1/20 0.46
PCNA P12004 3/20 0.46
TPMT P51580 1/20 0.44
KDM4E B2RXH2 2/20 0.41
CYP1A2 P05177 2/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
HIF1A Q16665 2/20 0.41
CYP2D6 P10635 1/20 0.41
PDE4A P27815 1/20 0.41
HDAC10 Q969S8 1/20 0.41
ABCB11 O95342 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5742010 0.84 PCNA (0.57) HDAC8THRATHRBPPARGRXRA
SCHEMBL5741745 0.82 HDAC6 (0.48) HDAC6HDAC8MEN1KMT2ATHRA
SCHEMBL5742233 0.81 KDM4E (0.60) MEN1KMT2AKDM4ESMN1; SMN2LMNA
SCHEMBL5743354 0.80 PCNA (0.54) HDAC6HDAC8MEN1KMT2ATHRA
SCHEMBL5741738 0.79 KDM4E (0.51) HDAC6HDAC8MEN1KMT2ATHRA
SCHEMBL5742684 0.79 EPHX2 (0.49) HDAC6HDAC8KMT2AKDM4ECYP1A2
SCHEMBL4684151 0.79 THRB (0.49) MEN1KMT2ATHRATHRBPPARG
SCHEMBL5899089 0.79 THRB (0.49) MEN1KMT2ATHRATHRBPPARG
SCHEMBL4684157 0.79 THRB (0.49) MEN1KMT2ATHRATHRBPPARG
SCHEMBL5742720 0.79 HDAC8 (0.56) HDAC6HDAC8MEN1KMT2ATHRA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1383729-A4 PEPTIDE DEFORMYLASE INHIBITORS SMITHKLINE BEECHAM CORP (US) 2006-04-19 EP claimed
US-20040267015-A1 Peptide deformylase inhibitors SMITHKLINE BEECHAM CORPORATION 2004-12-30 US claimed
EP-1383729-A1 PEPTIDE DEFORMYLASE INHIBITORS SmithKline Beecham Corporation (US) 2004-01-28 EP claimed
WO-2002081426-A1 PEPTIDE DEFORMYLASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2002-10-17 WO claimed
EP-1383729-A4 PEPTIDE DEFORMYLASE INHIBITORS SMITHKLINE BEECHAM CORP (US) 2006-04-19 EP disclosed
US-20040267015-A1 Peptide deformylase inhibitors SMITHKLINE BEECHAM CORPORATION 2004-12-30 US disclosed
EP-1383729-A1 PEPTIDE DEFORMYLASE INHIBITORS SmithKline Beecham Corporation (US) 2004-01-28 EP disclosed
WO-2002081426-A1 PEPTIDE DEFORMYLASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2002-10-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040267015-A1 Peptide deformylase inhibitors PDF, PEPD, DPEP1 HDAC6 1261/4885HDAC8 2220/4885MEN1 2559/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.